Clinical Trials Browser

Phase 2 × Breast Neoplasms × Vaccines × Clear all

NCT03630809 2022-04-25

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Phase 2 Terminated

Breast Neoplasms, Breast Neoplasms, Male